tiprankstipranks
Homology Medicines Inc (FIXX)
NASDAQ:FIXX

Homology Medicines (FIXX) Stock Forecast & Price Target

699 Followers
See the Price Targets and Ratings of:

FIXX Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Homology
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FIXX Stock 12 Month Forecast

There Are No Analyst Ratings for FIXX In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

FIXX Financial Forecast

FIXX Earnings Forecast

The previous quarter’s earnings for FIXX were -$5.00.
The previous quarter’s earnings for FIXX were -$5.00.

FIXX Sales Forecast

The previous quarter’s earnings for FIXX were $0.00.
The previous quarter’s earnings for FIXX were $0.00.

Detailed List of Analyst Forecasts​

Analyst Performance
Any
Any
Analyst Rating
Any
Any
Upside / Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird
$1.5
Hold
$1.50
(60.48% Upside)
Reiterated
11/16/23
Analysts' Opinions Are Mixed on These Healthcare Stocks: Homology Medicines (NASDAQ: FIXX), Align Tech (NASDAQ: ALGN) and Calidi Biotherapeutics (NYSE MKT: CLDI)
Credit Suisse
$1.7
Hold
$1.70
(81.88% Upside)
Reiterated
08/15/23
Homology Medicines (FIXX) PT Lowered to $1.70 at Credit SuisseCredit Suisse analyst Richard Law lowered the price target on Homology Medicines (NASDAQ: FIXX) to $1.70 (from $2.00) while maintaining a Neutral rating.
Oppenheimer
Hold
Assigned
07/31/23
H.C. Wainwright
$20
Buy
$20.00
(2039.72% Upside)
Reiterated
05/15/23
H.C. Wainwright Sticks to Their Buy Rating for Homology Medicines (FIXX)
Chardan Capital
$7
Buy
$7.00
(648.90% Upside)
Reiterated
05/11/23
Homology Medicines price target lowered to $7 from $8 at ChardanHomology Medicines price target lowered to $7 from $8 at Chardan
RBC Capital
$3
Hold
$3.00
(220.96% Upside)
Reiterated
05/11/23
Homology Medicines (FIXX) Gets a Hold from RBC Capital
Canaccord Genuity
$7
Buy
$7.00
(648.90% Upside)
Reiterated
04/06/23
Homology Medicines price target lowered to $7 from $19 at CanaccordHomology Medicines price target lowered to $7 from $19 at Canaccord
BTIG
$12
Buy
$12.00
(1183.83% Upside)
Reiterated
04/03/23
BTIG Sticks to Its Buy Rating for Homology Medicines (FIXX)

Best Analysts Covering Homology Medicines

Which Analyst Should I Follow If I Want to Buy FIXX and Sell After:
1 Month
xxx
Success Rate
6/14 ratings generated profit
43%
Average Return
-3.22%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of -3.22% per trade.
3 Months
xxx
Success Rate
2/9 ratings generated profit
22%
Average Return
-12.86%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 22.22% of your transactions generating a profit, with an average return of -12.86% per trade.
1 Year
Michelle GilsonCanaccord Genuity
Success Rate
0/9 ratings generated profit
0%
Average Return
-40.42%
reiterated a buy rating a year ago
Copying Michelle Gilson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.42% per trade.
2 Years
xxx
Success Rate
0/14 ratings generated profit
0%
Average Return
-61.74%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -61.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FIXX Analyst Recommendation Trends

Rating
May 23
Jun 23
Jul 23
Aug 23
Nov 23
Strong Buy
0
0
0
0
0
Buy
9
6
4
1
0
Hold
5
2
4
3
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
8
8
4
5
In the current month, FIXX has received 0 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. FIXX average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FIXX Stock Forecast FAQ

What is FIXX’s average 12-month price target, according to analysts?
Currently, no data Available
What is FIXX’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for FIXX, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is FIXX a Buy, Sell or Hold?
      Currently, no data Available
      What is Homology Medicines Inc’s price target?
      Currently, no data Available
      What do analysts say about Homology Medicines Inc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of FIXX?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis